reports
Outlook Therapeutics® Reports Financial Results for Second Quarter Fis...
Outlook Therapeutics® Reports Financial Results for Second Quarter Fiscal Year 2024 and Provides Corporate Update Positive opinion received from Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) for ONS-5010/LYTENAVA™ (bevacizumab gamma)United Kingdom (UK) Marketing Authorization Application (MAA) submitted NORSE EIGHT fully underway in the US; Topline readout expected in Q4 CY2024Resubmission of the ONS-5010 Biologics License Application (BLA) planned by the end of CY2024 Company to host inaugural quarterly update conference call and webcast on Th...
- Martin Fan
- Ritika Das
- Robert Driscoll
- Sam Ravina
- Wedbush Research
BLUE BLUEBIRD BIO INC.
TPH TRI POINTE HOMES INC.
TOL TOLL BROTHERS INC.
MTH MERITAGE HOMES CORPORATION
LGIH LGI HOMES INC.
LEN LENNAR CORPORATION CLASS A
KBH KB HOME
JACK JACK IN THE BOX INC.
FATE FATE THERAPEUTICS INC
CCS CENTURY COMMUNITIES INC.
BPMC BLUEPRINT MEDICINES CORP.
AZO AUTOZONE INC.
DHI D.R. HORTON INC.
TMHC TAYLOR MORRISON HOME CORPORATION
ORLY O'REILLY AUTOMOTIVE INC.
ACET ADICET BIO INC
BEAM BEAM THERAPEUTICS
COGT COGENT BIOSCIENCES INC
DFH DREAM FINDERS HOMES
NUVB NUVATION BIO INC (A)
TSVT 2SEVENTY BIO INC
GMTX GEMINI THERAPEUTICS INC
PEPG PEPGEN INC
SDHC SMITH DOUGLAS HOMES CORP
- David Carlson
- David Nierengarten
- Dennis Pak
- Martin Fan
- Ritika Das
- Robert Driscoll
- Sam Ravina
Taysha Gene Therapies Reports First Quarter 2024 Financial Results and...
Taysha Gene Therapies Reports First Quarter 2024 Financial Results and Provides Corporate Update Completed dosing in cohort one (low dose, 5.7x1014 total vg) of REVEAL Phase 1/2 adolescent and adult trial with longer-term data supporting the safety profile and durable response of TSHA-102; enrolled first patient in cohort two (high dose, 1x1015 total vg) with dosing scheduled for Q2 2024 Dosed second pediatric patient in cohort one (low dose, 5.7x1014 total vg) of REVEAL Phase 1/2 pediatric trial in Q1 2024 FDA granted Regenerative Medicine Advanced Therapy designation fol...
HealthEquity Closes Acquisition of BenefitWallet HSA Portfolio
HealthEquity Closes Acquisition of BenefitWallet HSA Portfolio Welcomes clients and members to its best-in-class platform DRAPER, Utah, May 14, 2024 (GLOBE NEWSWIRE) -- HealthEquity, Inc. (Nasdaq: HQY) ("HealthEquity"), the leader in Health Savings Account (HSA) and consumer-directed benefits administration, is pleased to announce the completed transfer of Conduent’s (Nasdaq: CNDT) BenefitWallet HSA portfolio. HealthEquity Chief Executive Officer, Jon Kessler said, "We are thrilled to welcome BenefitWallet clients and members as partners on our mission to save and improve lives by em...
Cartesian Therapeutics to Participate in the H.C. Wainwright 2nd Annua...
Cartesian Therapeutics to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ GAITHERSBURG, Md., May 13, 2024 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ:RNAC) (the “Company), a clinical-stage biotechnology company pioneering mRNA cell therapy for autoimmune diseases, today announced that management will participate in a fireside chat at the H.C. Wainwright 2nd Annual BioConnect Investor Conference on Monday, May 20, 2024, at 3:00 p.m. ET. A live webcast of the fireside chat is expected to be accessible in the Events section of the Company’...
Centessa Pharmaceuticals Reports Financial Results and Business Highli...
Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the First Quarter of 2024 Hemophilia Program: Ongoing registrational PRESent-2 and PRESent-3 studies of SerpinPC for the treatment of hemophilia B; PRESent-2 interim analysis planned in 2024Orexin Agonist Program: Cleared IND and initiated Phase 1 first-in-human clinical trial of ORX750, a highly potent and selective OX2R agonist for the treatment of narcolepsy; Clinical proof-of-concept data in acutely sleep-deprived healthy volunteers planned in 2H of 2024LockBody® Technology Platform: Ongoing Phase 1/2a study ...
Outlook Therapeutics® Announces UK Submission of Marketing Authorizati...
Outlook Therapeutics® Announces UK Submission of Marketing Authorization Application (MAA) for ONS-5010 as a Treatment for Wet AMD UK submission for national MAA review follows recently received positive opinion from Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) concerning the authorization of ONS-5010/LYTENAVA™ (bevacizumab gamma) ISELIN, N.J., May 13, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to achieve regulatory approval for the first authorized use of an ophthalmic formulatio...
- Jonathan Moreland
SHEN SHENANDOAH TELECOMMUNICATIONS COMPANY
SAIA SAIA INC.
RYI RYERSON HOLDING CORPORATION
RM REGIONAL MANAGEMENT CORP
RHP RYMAN HOSPITALITY PROPERTIES INC.
PENN PENN NATIONAL GAMING INC.
LTRX LANTRONIX INC.
KMPR KEMPER CORPORATION
HUBB HUBBELL INCORPORATED CLASS B
HOO HERBALIFE NUTRITION LTD.
FFIN FIRST FINANCIAL BANKSHARES INC
CTRN CITI TRENDS INC.
CNMD CONMED CORPORATION
AXS AXIS CAPITAL HOLDINGS LIMITED
AMH AMERICAN HOMES 4 RENT CLASS A
AIN ALBANY INTERNATIONAL CORP. CLASS A
HWBK HAWTHORN BANCSHARES
EFR ENERGY FUELS
SABR SABRE CORP.
ALPN ALPINE SELECT AG
HTLD HEARTLAND EXPRESS INC.
MAC MACERICH COMPANY
HI HILLENBRAND INC.
GLO CLOUGH GLOBAL OPPORTUNITIES FUND
WDFC WD-40 COMPANY
PK PARK HOTELS & RESORTS INC.
CRVS CORVUS PHARMACEUTICALS
MAV PIONEER MUNICIPAL HIGH INCOME ADVANTAGE TRUST
MHI PIONEER MUNICIPAL HIGH INCOME TRUST
EAF GRAFTECH INTERNATIONAL
FRAF FRANKLIN FINANCIAL SERVICES CO.
BBDC BARINGS BDC INC.
GH GUARDANT HEALTH
MCFT MASTERCRAFT BOAT HOLDINGS
HQL TEKLA LIFE SCIENCES INVESTORS
CZR CAESARS ENTERTAINMENT INC
WSC WILLSCOT MOBILE MINI HOLDINGS CORP
PSTV PLUS THERAPEUTICS INC
CTOS CUSTOM TRUCK ONE SOURCE
TBBK INC.
MEGI THE BANCORP
NPCT INC.
RXO_w MAINSTAY CBRE GBL INFRASTRUCTURE MEGATRENDS FD
BYON NUVEEN CORE PLUS IMPACT FD
VSTS_w RXO INC
NBBK BEYON 3D LTD
ASGI VESTIS CORPORATION
EYPT NB BANCORP INC.
DBD ABERDEEN STANDARD GLOBAL INFRASTRUCTURE INCOME FUND
EYEPOINT PHARMACEUTICALS
INC.
DIEBOLD NIXDORF INCORPORATED
- Martin Fan
- Ritika Das
- Robert Driscoll
- Sam Ravina
- Valens Research
Valens Equity Weekly Insights - 2024 05 07
Kinder Morgan (KMI) is the biggest natural gas pipeline company in the U.S. Its dominant position has allowed it to have stable profitability the last several years even when natural gas prices and volumes were low. Now that the natural gas market is improving thanks to better compression technology and higher demand from Europe, Kinder Morgan can start making more money on its contracts. Uniform Accounting highlights that the market is not pricing in a profitability inflection for the company,...
Quest Resource Holding Corporation Reports First Quarter 2024 Financia...
Quest Resource Holding Corporation Reports First Quarter 2024 Financial Results Double-Digit Growth in Gross Profit Resulting from Business Expansion and Efficiency Gains Significant New Business Wins and Pipeline Growth Reflect Company’s Strong Value Proposition and Momentum Investor Conference Call & Webcast to be held at 5pm ET on Thursday, May 9, 2024 THE COLONY, Texas, May 09, 2024 (GLOBE NEWSWIRE) -- Quest Resource Holding Corporation (NASDAQ: QRHC) (“Quest”), a national leader in environmental waste and recycling services, today announced financial results for the first quarter ...
Outlook Therapeutics® to Report Financial Results for Second Quarter F...
Outlook Therapeutics® to Report Financial Results for Second Quarter Fiscal Year 2024 on May 16, 2024 and Host Inaugural Quarterly Conference Call and Webcast ISELIN, N.J., May 09, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to achieve the first approval for an ophthalmic formulation of bevacizumab for the treatment of retinal diseases in the US and the EU, today announced that it will report its financial results for second quarter fiscal year 2024 on Thursday, May 16, 2024. Outlook Therapeutics management will host its inaugur...
- Jonathan Moreland
RM REGIONAL MANAGEMENT CORP
PENN PENN NATIONAL GAMING INC.
HOO HERBALIFE NUTRITION LTD.
FFIN FIRST FINANCIAL BANKSHARES INC
CNMD CONMED CORPORATION
AXS AXIS CAPITAL HOLDINGS LIMITED
AMH AMERICAN HOMES 4 RENT CLASS A
EFR ENERGY FUELS
MAC MACERICH COMPANY
CTOS CUSTOM TRUCK ONE SOURCE
TBBK INC.
VSTS_w THE BANCORP
EYPT INC.
VESTIS CORPORATION
EYEPOINT PHARMACEUTICALS
INC.
Lesaka Q3 2024 Results: Lesaka continues to deliver improved profitabi...
Lesaka Q3 2024 Results: Lesaka continues to deliver improved profitability JOHANNESBURG, South Africa, May 08, 2024 (GLOBE NEWSWIRE) -- Lesaka Technologies, Inc. (Nasdaq: LSAK; JSE: LSK) today released results for the third quarter ended March 31, 2024 (“Q3 2024”). Performance Highlights for Q3 2024: Revenue of $138.2 million (ZAR 2.6 billion)1 in Q3 2024, compared to $134.0 million (ZAR 2.4 billion)1 for the third quarter ended March 31, 2023 (“Q3 2023”), an increase of 9% in South African Rand (“ZAR”).Operating income of $0.8 million (ZAR 15.0 million) for the quarter, compared to an ...
Vintage Wine Announces Forbearance Agreement Extension with Lenders
SANTA ROSA, Calif.--(BUSINESS WIRE)-- (Nasdaq: VWE and VWEWW) (the “Company”) today announced that the Company and its lender group have amended the amended and restated forbearance agreement dated April 2, 2024 (as amended, the “amended forbearance agreement”) to extend the forbearance period to June 4, 2024. The lenders have also agreed to defer the $10 million principal payment previously due at May 15, 2024 to June 17, 2024. Under the amendment to the amended and restated forbearance agreement, the lender group has agreed to not exercise any rights and remedies until June 4, 2024, so lo...
Cartesian Therapeutics Reports First Quarter 2024 Financial Results an...
Cartesian Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update Topline data from Phase 2b trial of Descartes-08, the Company’s potential first-in-class mRNA CAR-T cell therapy, in myasthenia gravis on track for mid-2024 On track to dose first patient in Phase 2 trial of Descartes-08 in SLE in 2Q24, as well as Phase 2 basket studies in additional autoimmune indications in 2H24 New headquarters expected to support scale of wholly owned, in-house cGMP manufacturing capabilities for clinical and commercial supply of Com...
- Jay Kornreich
- Richard Anderson
- Sydnie Rohme
AbCellera Reports Q1 2024 Business Results
VANCOUVER, British Columbia--(BUSINESS WIRE)-- (Nasdaq: ABCL) today announced financial results for the first quarter of 2024. All financial information in this press release is reported in U.S. dollars, unless otherwise indicated. “We continue to execute on advancing our internal pipeline, completing capital investments in forward integration, and expanding strategic partnerships,” said Carl Hansen, Ph.D., founder and CEO of AbCellera. “This quarter, presentations on our T-cell engager platform, which includes our highly differentiated CD3 panel, demonstrated how we can repeatedly generate...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.